Energy

Cameco Corporation (CCJ)

$44.8B
Market Cap
106.0
P/E Ratio
0.97
Beta
0.17%
Dividend Yield
Piotroski 8/9Altman Z 9.2 SafeBeneish M -2.80 CleanROIC−WACC -3.2%

Quantitative Summary

Deterministic

CCJ trades at 106.0x earnings — a 205% premium to its sector average of 34.8x — without a dominant ROIC-WACC spread. Financial health metrics are strong: Piotroski 8/9, Altman Z 9.2 (above 3.0 safe zone threshold).

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

Cameco Corporation presents a fundamental dichotomy characterized by exceptional financial stability yet suboptimal capital efficiency. While the Piotroski F-Score of 8/9 and Altman Z-Score of 9.2 signal robust balance sheet health and low bankruptcy risk, the negative ROIC-WACC spread of -3.2% indicates that current operations are destroying value relative to the cost of capital. This inefficiency is driven by a DuPont-style reliance on high margins rather than leverage or turnover; specifically, strong net and gross margins support an 11.0% revenue growth trajectory, yet these operational strengths fail to offset the widening gap between returns generated and costs incurred. Consequently, despite evidence of earnings quality suggested by the negative Beneish M-Score, the core economic engine lacks the spread necessary for sustainable value creation under current pricing assumptions.

Valuation metrics suggest a significant market premium that diverges sharply from intrinsic models and sector norms. The stock trades at 106.0x forward earnings, which is more than three times the energy sector average of 31.0x, implying the market prices in exceptional future growth or scarcity dynamics not yet realized in fundamentals. This disconnect between current multiples and a DCF-derived fair value of $79 suggests that prevailing valuations assume a level of expansion or margin persistence inconsistent with the observed negative capital returns. Investors must weigh whether the premium reflects unique supply-side constraints specific to uranium or represents an overextension given the company's inability to generate returns exceeding its weighted average cost of capital.

The risk/reward profile appears skewed toward downside volatility if growth expectations normalize, as the high valuation leaves little margin for error regarding future operational performance. While insider activity and Fama-French alpha data were not provided in this dataset, the structural tension between a pristine balance sheet score and negative value spread creates an environment where any stumble in revenue execution could trigger multiple compression disproportionate to earnings changes. The market appears to be pricing in a growth narrative that currently lacks support from capital allocation efficiency metrics.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →8.7%10.7%12.7%
2%$95$72$57
3%$110$79$61
4%$130$89$67

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=10.7%, terminal growth 3%. Fair value $79 (+0.0%). Not investment advice.

Valuation Context

106.0x
CCJ P/E
34.8x
Sector Avg
+205%
vs Sector

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

8/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
9.2
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.80
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

27.9%
Gross Margin
16.9%
Net Margin
7.5%
ROIC
10.7%
WACC
ROIC − WACC Spread: -3.2%— Negative spread.
+11.0%
Revenue Growth (YoY)
+243.1%
Earnings Growth (YoY)
1.1B
Free Cash Flow
10%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

Balance Sheet Health

0.49x
Debt / Equity
2.47x
Current Ratio
9.1x
Interest Coverage
-0.1x
Net Debt / EBITDA
2.41%
FCF Yield
1.2B
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $0.19
Act: $0.16
-17.5%
Q3
✓ Beat
Est: $0.52
Act: $0.71
+37.6%
Q2
✗ Miss
Est: $0.27
Act: $0.07
-74.5%
Q1
✓ Beat
Est: $0.44
Act: $0.50
+12.9%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

56.3
Forward P/E
PEG Ratio
9.02
Price/Book
4M
Avg Volume
$135.24
52W High
$35.00
52W Low
52W Range Position

ETF Contagion Visualizer

Simulate a price drop in Cameco Corporation to visualize passive redemption contagion across ETFs and collateral stocks.

CCJ Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
CCJEpicenterARKQETFTSLALow RiskAMDLow RiskTERLow RiskRKLB UQUnknownKTOSLow Risk
CCJ Price Drop (%)0

If Cameco Corporation (CCJ) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies TESLA INC (TSLA) as the most exposed collateral stock, sharing 1 ETFs with CCJ. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 1 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

CCJ Ownership Dynamics

Ticker
CCJ

ETFs with Highest CCJ Exposure

Float lock-up computed from 1 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

CCJ Capital Efficiency

How efficiently does Cameco Corporation convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$1.1B
EBITDA
$1.2B
FCF Conversion
92%
Reinvestment Rate
8%
92% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
7.5%
ROIC − WACC Spread
-3.2%

Cameco Corporation converts 92% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. However, the ROIC-WACC spread is negative (-3.2%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-1367$116.93$7,834.31
2026-05-085,320$118.71$631,537.2
2026-05-0718,482$123.76$2.3M
2026-05-05976$118.26$115,421.76
2026-05-0415,629$120.60$1.9M
2026-05-0117,472$123.04$2.1M
2026-04-30130$114.29$14,857.7
2026-04-27100$122.15$12,215
2026-04-22254$116.61$29,618.94
2026-04-211,799$123.62$222,392.38
2026-04-2023,839$120.66$2.9M
2026-04-136,700$116.04$777,468
2026-04-062,500$112.57$281,425
2026-03-272,613$104.67$273,502.71
2026-03-2531$108.04$3,349.24
2026-03-162,000$107.92$215,840
2026-03-1210,025$115.39$1.2M
2026-03-11267$120.08$32,061.36
2026-03-054,094$120.24$492,262.56
2026-03-03170$125.74$21,375.8
2026-02-2321,734$121.35$2.6M
2026-02-1813,922$112.94$1.6M
2026-02-0321,573$120.21$2.6M
2026-02-02200$123.39$24,678
2026-01-2933$134.09$4,424.97
2026-01-2849$125.97$6,172.53
2026-01-279$121.26$1,091.34
2026-01-262,550$124.04$316,302
2026-01-224,247$122.33$519,535.51
2026-01-20111,792$116.44$13.0M

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Compare CCJ to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.